Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Difelikefalin - Tvardi Therapeutics

Next Previous
Drug Profile

Difelikefalin - Tvardi Therapeutics

Alternative Names: CKD-943; CR-845; CR845/difelikefalin; Difelikefalin acetate - Tvardi Therapeutics; FE-202845; Kapruvia; KORSUVA; Korsuva; MR13A9

Latest Information Update: 23 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Chong Kun Dang; CSL Vifor; Kissei Pharmaceutical; Maruishi Pharmaceutical; Tvardi Therapeutics; Vifor Fresenius Medical Care Renal Pharma
  • Class Amines; Analgesics; Antipruritics; Carboxylic acids; Opioid analgesics; Peptides; Piperidines; Skin disorder therapies; Urologics
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Pain; Postoperative pain

Highest Development Phases

  • Marketed Pruritus
  • Phase III Pain; Postoperative pain

Most Recent Events

  • 15 Apr 2025 Cara Therapeutics has merged with Tvardi Therapeutics to form Tvardi Therapeutics
  • 25 Sep 2024 Vifor Fresenius Medical Care Renal Pharma completes a phase III trial in Pruritus in China (IV) (NCT05885737)
  • 19 Sep 2024 Vifor Fresenius Medical Care Renal Pharma plans a phase II trial for Pruritus (In children, In adolescents) in January 2025 (IV) (NCT06593392)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top